Monitor pricing terms and Nasdaq approval decision—this offering is essential for funding near-term clinical milestones. The company's history of delinquency and going concern risk makes execution risk high; watch for any updates on uplisting progress.
Executive Summary
Eloxx Pharmaceuticals filed an S-1 registration statement for a proposed public offering of common stock and pre-funded warrants, aiming to raise up to $50 million to fund its lead candidate exaluren through Phase 2b trials for Alport syndrome and a Phase 2 trial for ADPKD. The company is currently delinquent in SEC filings, trades on the OTC Expert Market after Nasdaq delisting in 2023, and has substantial doubt about its ability to continue as a going concern without this offering.
Key Facts
- Maximum aggregate offering amount of $50 million, with proceeds intended to fund exaluren Phase 2b trial (NMAS) and Phase 2 trial (nmADPKD) plus working capital
- Net loss of $6.0 million in 2025, $3.1 million in 2024, and $17.1 million in 2023; accumulated deficit of $304.3 million as of March 31, 2026
- Cash and cash equivalents of $6.4 million as of March 31, 2026; the company has a going concern opinion from its auditors
- Common stock delisted from Nasdaq in October 2023; seeking uplisting to Nasdaq Capital Market contingent on this offering
- Lead product candidate exaluren has completed a Phase 2a trial in Alport syndrome; Phase 2b expected to start Q3 2026 with topline data by mid-2027
- License agreement with Almirall for ZKN-013; received $6 million in upfront and milestone payments in 2024
Financial Impact
Offering up to $50 million; net proceeds after underwriting discounts and expenses unknown at this time
Risk Factors
- Failure to complete offering would likely force significant cost reductions or business cessation
- Potential Nasdaq uplisting denial would prevent the offering from closing
- High dilution from pre-funded warrants and additional equity issuance
- Clinical trial risk: exaluren has limited Phase 2a data and FSD not validated as surrogate endpoint
- Material weakness in internal controls identified; remediation uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001193125-26-212324 |
| Document: d35071dex1058.htm | 0001193125-26-212324 |
| Document: d35071dexfilingfees.htm | 0001193125-26-212324 |
| Document: d35071dex231.htm | 0001193125-26-212324 |
| Document: 0001193125-26-212324-index-headers.html | 0001193125-26-212324 |
| Document: 0001193125-26-212324-index.html | 0001193125-26-212324 |
| Document: 0001193125-26-212324.txt | 0001193125-26-212324 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $13.12 | awaiting T+20 | — | $12.80 (−2.44%) |
Sep 21, 2026 5w ago | EFFECT | $17.19 $12.50 | ▼ −27.28% | ▼ −26.38% | $12.80 (−25.54%) |
Sep 11, 2026 6w ago | S-1 | $16.30 | awaiting T+20 | — | $12.80 (−21.47%) |
Jun 9, 2026 19w ago | EFFECT | $11.01 $10.95 | ▼ −0.55% | ▼ −1.99% | $12.80 (+16.26%) |
Jun 4, 2026 20w ago | S-1/A | $6.20 | awaiting T+20 | — | $12.80 (+106.45%) |
Jun 1, 2026 21w ago | S-1/A | $1.51 | awaiting T+20 | — | $12.80 (+747.68%) |
Jun 1, 2026 21w ago | 8-K | $4.07 $13.88 | ▲ +241.03% | ▲ +242.33% | $12.80 (+214.50%) |
May 7, 2026 24w ago | S-1 | $1.43 | awaiting T+20 | — | $12.80 (+794.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers